The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,177,423 | -8,867,798 |
| Depreciation and amortization | 4,102 | 9,075 |
| Non-cash lease adjustments | 146,895 | - |
| Issuance of restricted stock for services | 134,100 | - |
| Stock-based compensation | 143,685 | 308,376 |
| Accretion of discounts on available for sale debt securities, net | 38,015 | 132,925 |
| Foreign currency remeasurement gain | 8,912 | 129,565 |
| Realized gain on redemptions of available for sale debt securities | -345 | 22,634 |
| Realized loss on equity securities | 72,677 | 142,248 |
| Unrealized gain on equity securities | 95,906 | 167,389 |
| Prepaid expenses and other current assets | -201,223 | 62,133 |
| Other assets | - | 0 |
| Accounts payable and accrued expenses | -806,921 | 611,731 |
| Changes in operating right-of-use assets | - | 96,745 |
| Operating lease liabilities | -51,085 | -98,618 |
| Net cash flows used in operating activities | -4,571,980 | -8,312,887 |
| Purchase of property and equipment | 555 | 1,159 |
| Purchases of marketable securities | 2,076,794 | 8,440,696 |
| Redemptions of marketable securities | 8,005,887 | 15,274,344 |
| Net cash flows provided by (used in) investing activities | 5,928,538 | 6,832,489 |
| Net proceeds from the issuance of common stock, net of issuance costs of 30,722 | 958,339 | - |
| Proceeds from warrant exercises | - | 0 |
| Proceeds from option exercises | 13,442 | - |
| Net cash flows provided by financing activities | 971,781 | 0 |
| Effect of foreign exchange rates on cash | -261 | 30,727 |
| Change in cash and cash equivalents for the period | 2,328,078 | -1,449,671 |
| Cash and cash equivalents at beginning of period | 7,511,079 | - |
| Cash and cash equivalents at end of period | 8,389,486 | - |
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)